Suchergebnisse - "Grande, Enrique"

PubPharm (5)

1

Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130) : final overall survival analysis results from a randomised, controlled, phase 3 study

enthalten in: The Lancet. Oncology | 2024

von Grande, E. | Arranz, J. | De Santis, M. | +20

2

Atezolizumab monotherapy versus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130) : final overall survival analysis from a randomised, controlled, phase 3 study

enthalten in: The Lancet. Oncology | 2024

von Bamias, A. | Davis, I. | Galsky, M. | +21

3

Tailored immunotherapy approach with nivolumab with or without nivolumab plus ipilimumab as immunotherapeutic boost in patients with metastatic renal cell carcinoma (TITAN-RCC) : a multicentre, single-arm, phase 2 trial

enthalten in: The Lancet. Oncology | 2023

von Grimm, M. | Esteban, E. | Barthélémy, P. | +40

4

177Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1) : final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial

enthalten in: The Lancet. Oncology | 2021

von Strosberg, J. | Caplin, M. | Kunz, P. | +18

CommentIn: Lancet Oncol. 2021 Dec;22(12):1645-1646. - PMID 34793720

5

Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE) : overall survival and updated results of a randomised, double-blind, phase 3 trial

enthalten in: The Lancet. Oncology | 2020

von Petrylak, D. | de Wit, R. | Chi, K. | +143

CommentIn: Lancet Oncol. 2020 Jan;21(1):11-13. - PMID 31753728

1
[1]